文献速递乳腺癌放疗放疗物理与技术

Neo-CheckRay 试验中术前免疫调节乳腺 iSBRT 的靶区勾画与治疗计划

Adapting radiation therapy to immunotherapy: Delineation and treatment planning of pre-operative immune-modulating breast iSBRT in 151 patients treated in the randomized phase II Neo-CheckRay trial.
PubMed 文献 · Radiother Oncol · 2025-03-06

Neo-CheckRay 随机多中心 II 期试验在高危 luminal B 早期乳腺癌中评估术前免疫调节 SBRT(8 Gy×3 次)联合化疗±durvalumab/oleclumab。本文报告该试验所用剂量约束并对全部 151 例治疗计划行剂量学分析,重点关注肿瘤引流淋巴结(TDLN)剂量。结果表明预设危及器官剂量约束可行,TDLN 得到充分保护。

要点

  • 皮肤 D0.1cc<19.2 Gy、胸壁 D1cc<15 Gy、同侧未受累乳腺 V24Gy<30%。
  • 通过避免入射或出射束经过 TDLN 来降低其剂量。
  • 151 例中 GTV 的 V95% 中位 97.4%,PTV 的 V95% 中位 95.5%。

核心结论

  • 在 Neo-CheckRay 试验中,预设的危及器官剂量约束是可行的,TDLN 得到了充分保护。

研究设计与样本

  • 随机多中心 II 期 Neo-CheckRay 试验,术前 iSBRT 8 Gy×3 次联合化疗±抗 PD-L1 durvalumab 和抗 CD73 oleclumab,用于早期高危 luminal B 乳腺癌。
  • iSBRT 仅照射原发乳腺癌以发挥免疫调节潜力,并保护肿瘤引流淋巴结(TDLN)以避免放疗诱导的免疫抑制。
  • 收集该试验全部 151 例患者的 DICOM-RT 数据,分析靶区、危及器官及 TDLN 剂量。
  • TDLN 体积包括内乳淋巴结(IMN)和腋窝 I-IV 站(含胸肌间淋巴结)。

主要发现

  • 151 例中 GTV 的 V95% 中位为 97.4%(90% CI 26.5-100),PTV 的 V95% 中位为 95.5%(90% CI 56.1-100)。
  • 所有 TDLN 体积的平均剂量(dMean)<1 Gy。
  • TDLN 中 dMean 最高者为 IMN 0.8 Gy(90% CI 0.1-2.7)和腋窝 1 站 0.6 Gy(90% CI 0.0-3.9)。
  • 若存在受累淋巴结,其 dMean 为 0.3 Gy(90% CI 0.0-5.0)。

关键数值与推荐

  • 皮肤约束:D0.1 cc<19.2 Gy。
  • 胸壁约束:D1cc<15 Gy。
  • 同侧未受累乳腺约束:V24Gy<30%。
  • 通过避免入射或出射束经过 TDLN 来降低 TDLN 剂量。

临床怎么用

  • 术前乳腺 iSBRT 8 Gy×3 次可参照本试验的皮肤、胸壁及同侧未受累乳腺剂量约束进行计划设计。
  • 计划设计时应避免入射或出射束经过 TDLN,以降低 IMN 和腋窝各站剂量。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: The randomized multicentric phase II Neo-CheckRay trial investigated preoperative immune-modulating stereotactic body radiation therapy (iSBRT) 8 Gy x 3 fractions in combination with chemotherapy with or without the anti PD-L1 durvalumab and the anti-CD73 oleclumab in early-stage, high-risk, luminal B breast cancer. iSBRT was solely delivered to the primary breast cancer leveraging on its immune modulating potential to sustain an anti-tumour response. To avoid immunosuppression induced by radiation therapy (RT), the tumour draining lymph nodes (TDLN) were spared. Here, we present the constraints used in the Neo-CheckRay trial and a dosimetric analysis of all delivered treatment plans with a special focus on the dose to the TDLN. MATERIALS AND METHODS: Main constraints were the skin (D0.1 cc < 19.2 Gy), chest wall (D1cc < 15 Gy) and ipsilateral uninvolved breast (V24Gy < 30 %). The dose to the TDLN was reduced by avoiding beams entering or exiting the TDLN. In the present work, the DICOM-RT data of all the patients treated in the Neo-CheckRay trial were collected (n = 151) to describe doses to the target volume, to the organs at risk and the TDLN. The TDLN volumes consisted of the internal mammary nodes (IMN) and the axilla levels I-IV including the interpectoral nodes. RESULTS: In 151 patients, the median V95% of the gross target volume (GTV) and planning target volume (PTV) were 97.4 % (90 % CI 26.5-100) and 95.5 % (56.1-100). The mean dose (dMean) to all TDLN volumes was < 1 Gy. The highest dMean were to the IMN and axilla level 1: 0.8 Gy (90 % CI 0.1-2.7) and 0.6 Gy (0.0-3.9), respectively. The dMean to the involved lymph nodes, if present, was 0.3 Gy (0.0-5.0). CONCLUSION: In the Neo-CheckRay trial, the predefined organs at risk dose constraints were feasible and the TDLN were adequately spared.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. De Caluwé A, Bellal S, Cao K, et al. Adapting radiation therapy to immunotherapy: Delineation and treatment planning of pre-operative immune-modulating breast iSBRT in 151 patients treated in the randomized phase II Neo-CheckRay trial. Radiother Oncol. 2025. PMID: 40057199. doi:10.1016/j.radonc.2025.110836

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。